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Abstract 
Parkinson’s Disease (PD) is a motor disorder with symptoms including resting tremor, akinesia, 
bradykinesia, and rigidity. A major neuropathological feature of PD is degeneration of 
nigrostriatal dopamine (DA) neurons. The resulting DA depletions lead to the production of 
severe motor deficits. Pharmacological agents that reduce DA transmission can also induce these 
motor abnormalities. In addition to the involvement of DA, drugs acting on acetylcholine, 
namely cholinomimetics, can induce or exacerbate Parkinsonian symptoms. In humans, one of 
the main motor symptoms associated with PD is resting tremor, occurring at a frequency of 3-7 
Hz. This can be modeled in rodents using a tremulous jaw movement (TJM) model; these 
movements are defined as rapid, repetitive, vertical deflections of the lower jaw that are not 
directed at any particular stimulus. In rodents, TJMs are induced using the same pharmacological 
agents that induce Parkinsonism in humans, including neurotoxic or pharmacological depletion 
of striatal dopamine, dopamine depleting agents, such as tetrabenazine (TBZ), dopamine 
antagonists, and cholinomimetics, such as pilocarpine. Moreover, TJMs in rodents can be 
attenuated by antiparkinsonian agents, including L-DOPA, dopamine agonists, muscarinic 
antagonists, and adenosine A2A antagonists. In human Parkinsonian patients, exaggerated 
physiological synchrony is seen in the beta frequency band in various parts of the cortical/basal 
ganglia/thalamic circuitry, and activity in the tremor frequency range (3-7 Hz) also has been 
recorded. In past studies, local field potentials (LFPs) have been recorded from PD patients 
undergoing implantation of stimulating electrodes in the subthalamic nucleus (STN). It has been 
shown that there is a high degree of coherence between STN LFPs and tremor as measured by 
EMG in PD patients. This study was done to determine if tremor-related local field potential 
(LFP) activity could be recorded from motor cortex or subthalamic nucleus during the TJMs 
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induced by the muscarinic agonist pilocarpine, which is a well-known tremorogenic agent.  
Pilocarpine induced a robust TJM response that was marked by rhythmic electromyographic 
activity in the temporalis muscle. Compared to periods with no tremor activity, TJM epochs were 
characterized by increased LFP activity in the tremor frequency range in both neocortex and 
subthalamic nucleus. Tremor activity was not associated with increased activity in the beta 
frequency band. These studies identified tremor-related LFP activity in parts of the cortical/basal 
ganglia circuitry that are involved in the pathophysiology of Parkinsonism, which may ultimately 
lead to identification of the oscillatory neural mechanisms involved in the generation of 
tremulous activity, as well as novel treatments for tremor disorders. 
 
1. Introduction 
Parkinsonism is a broad family of motor movement disorders that includes idiopathic 
Parkinson’s disease (PD) and drug-induced Parkinsonism (DIP), as well as pugilistic and post-
encephalic Parkinsonism. PD results from the death of dopamine (DA) producing cell bodies in 
the Substantia Nigra Pars Compacta, causing a degeneration of nigrostriatal DA neurons 
(Hornykiewicz, 1973), It is progressive neurodegenerative disease that will affect muscles 
throughout the entire body and can lead to a decrease in cognitive skills over many years. There 
are millions of cases known worldwide, with 1-2 million diagnosed in the United States. PD is 
the second most common neurodegenerative known disorder, with a prevalence of 1-2% in 
people over age 65 and 3% prevalence in those over age 85. Age is the strongest risk factor for 
PD and given the aging of the population, prevalence is expected to increase dramatically over 
the next decade.  
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DIP is induced by drugs that interfere with DA transmission (e.g. DA antagonists, DA 
depleting agents; Marsden et al., 1975; McEvoy, 1983), and cholinomimetics such as 
anticholinesterases and muscarinic agonists (Ott and Lannon, 1992; Aarsland et al., 2003). The 
cardinal motor symptoms of Parkinsonism include akinesia, bradykinesia, rigidity, and resting 
tremor, which typically occurs in the 3-7 Hz frequency range (Marsden et al., 1975). 
Parkinsonian symptoms including tremor are produced by a cascade of neurochemical and 
physiological events involving transmitters in various parts of basal ganglia circuitry (Salamone 
et al. 1998).  
In addition to the involvement of DA, drugs acting on acetylcholine (cholinomimetics) 
also can induce or exacerbate Parkinsonian symptoms, including tremor, in humans, and 
muscarinic acetylcholine antagonists often are used as antiparkinsonian agents that can suppress 
tremor. Tremor is defined as a “periodic oscillation of a body member” (Findley and Gresty, 
1981), and can be a feature of several different movement disorders. Tremors are classified in 
various ways, including the state under which they occur (e.g., resting tremor, action tremor), 
their local frequency, and pathological conditions associated with tremor. 
Relatively few clinical studies have specifically emphasized the pharmacology of tremor, 
and there is considerable uncertainty about the neurochemical mechanisms that underlie 
tremorogenesis (Deuschl et al. 2000).  For these reasons, it is important to focus attention on the 
pharmacology, neurochemistry, and physiology of tremor, and studies employing animal models 
are a critical aspect of this research strategy. Drug-induced tremulous jaw movements are a 
model of Parkinsonian tremor (Salamone et al. 1998, 2005). DIP is produced in rodents by the 
same pharmacological agents that induce human Parkinsonism, and resting tremor can be 
modeled in rodents using the tremulous jaw movement (TJM) model. TJMs are defined as 
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“rapid, repetitive vertical deflections of the lower jaw that resemble chewing but are not directed 
at any particular stimulus”, and this model has become an extensively validated model of 
Parkinsonian resting tremor in rodents (Salamone et al. 1998). TJMs occur in phasic bursts of 
activity in the 3-7 Hz local frequency range, which resembles the frequency of Parkinsonian 
resting tremor (Salamone et al., 1998; Cousins et al., 1998; Collins et al., 2010; Podurgiel et al., 
2013b).  
More recently, there has been substantial interest in DA/adenosine receptor interactions, 
as adenosine A2A receptors are highly expressed in neostriatum. A2A antagonists exert motor 
effects in rodents and primates that are consistent with antiparkinsonian actions, including 
suppression of TJMs (Correa et al. 2004; Salamone et al. 2008). TJMs in rats can be induced by 
several DAergic conditions that are known to be associated with Parkinsonism in humans, 
including neurotoxic depletion of striatal DA (Jicha and Salamone, 1991), reserpine (Baskin and 
Salamone, 1993; Salamone and Baskin, 1996; Salamone et al. 2008), and DA antagonists (i.e., 
Jicha and Salamone, 1991).  TJMs can also be induced by muscarinic agonists (Salamone et al. 
1986; Salamone et al. 1990) and anticholinesterases such as physostigmine, tacrine or 
galantamine (Mayorga et al. 1997). TJMs can be attenuated by co-administration of 
antiparkinsonian drugs from several different classes, such as L-DOPA, DA agonists, muscarinic 
antagonists, MAO inhibitors, and adenosine A2A antagonists (Cousins et al., 1997; Simola et al., 
2004, 2006; Salamone et al., 2005, 2008a,b; Podurgiel et al., 2013a,b). Considerable evidence 
indicates that TJMs in rodents are a valid model for the exploration of the pharmacology, 
neurochemistry and physiology of drug-induced tremor (Salamone et al., 1998, 2008b, 2013; 
Collins-Praino et al., 2011; Podurgiel et al., 2013a,b, 2015). Furthermore, TJMs can be 
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attenuated by deep brain stimulation of the subthalamic nucleus (Collins-Praino et al. 2012), 
which is a major brain target in human deep brain stimulation Parkinsonism treatments. 
There have been physiological measurements of oscillatory activity in the basal ganglia 
circuits and cortex in humans with PD as well as in animal models. The best characterized 
oscillation depicting the exaggerated neuronal synchrony found in the basal ganglia and cortex of 
PD patients is the beta band, which is at about 15-30 Hz (Brown 2003; Hammond et al., 2007; 
Oswal et al., 2013). Increased beta activity has been observed within the cortex (George et al., 
2013) and subthalamic nucleus (STN) of PD patients, and it has been suggested that exclusive 
synchrony in this frequency range contributes to motor dysfunction (Levy et al., 2002; Brown and 
Williams, 2005; Kuhn et al., 2006).  This has been demonstrated in terms of increases in 
oscillatory activity in the discharge of single neurons, increased amplitude of local field potentials 
(LFPs), and increased coherence of LFP signals across different basal ganglia structures in patients 
undergoing surgical procedures (Hutchison et al., 2004; Hammond et al., 2007).  LFPs reflect 
synchronous synaptic input onto the somatodendritic field of multiple adjacent neurons 
(Creutzfeldt et al., 1966).  Thus, an increase in the amplitude or change in frequency of the LFP 
can reflect increasing synchrony among a population of input neurons, or a change in the 
frequency of a population input (see Buzsaki and Chrobak, 1995). Increases in synchrony result 
from increased periodic discharge of individual neurons, or more typically from altered temporal 
organization of a group of neurons, in which any one neuron may or may not be oscillatory, but the 
population exhibits a repeating (oscillatory) temporal structure (see Buzsaki and Chrobak, 1995).  
Reduction in STN beta activity correlates with improvement in akinesia and rigidity in 
PD patients (Levy et al., 2002; Kuhn et al., 2006). While the literature supports a link between 
increased cortical and basal ganglia beta power and the development of akinesia/rigidity, beta 
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activity generally does not correlate with the severity of resting tremor (Kuhn et al., 2005; 
Hammond et al., 2007; Oswal et al., 2013). Rather, the development of tremor in PD patients has 
been shown to be associated with the emergence of oscillations in the tremor frequency range (3-
7 Hz) in the cortex and basal ganglia (Timmerman et al., 2003; Reck et al., 2009; Hirschmann et 
al., 2013; Oswal et al., 2013). Timmerman et al. (2003) reported strong coherence between 
electromyograph (EMG) activity of forearm muscles and activity in the contralateral primary 
motor cortex (M1), at tremor (3-7 Hz) and double tremor frequency (7-13 Hz) in PD patients off 
medication. Similar patterns of activity have been observed in the STN of PD patients, as 
indicated by power spectra peaks at tremor frequency and tremor harmonics, as well as 
significant coherence between STN LFPs and EMG activity at tremor frequency (Brown et al., 
2001; Levy et al., 2000; Liu et al., 2002; Wang et al., 2005; Reck et al., 2009).  
These clinical reports support the idea that cortical and STN power and coherence at 
tremor frequencies increase with the manifestation of tremor, but this phenomenon has not been 
modeled in rodents. Therefore, the present study characterized the temporal pattern of oral EMG 
activity and associated changes in LFPs recorded from M1 and STN during the TJMs induced by 
the non-selective muscarinic agonist pilocarpine (Collins et al., 2010; Collins-Praino et al., 2012; 
Salamone et al., 2013). 
 
2. Materials and Methods 
2.1. Animals 
A total of 5 adult male Sprague Dawley rats (Harlan Sprague Dawley, Indianapolis, IN) 
with no prior drug experience were used in the present experiment. The rats weighed 350-450 g 
during the course of the experiment and had ad libitum access to lab chow and water. Animals 
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were group-housed prior to surgery in a colony that was maintained at approximately 23°C and 
had a 12-hour light/dark cycle (lights on at 0700 hrs).  Post-surgery, animals were single housed 
to avoid over grooming around the surgical implant. This study was conducted according to 
University of Connecticut and NIH guidelines for animal care and use. 
2.2 Drug Treatment Procedures and Dose Selection 
Pilocarpine was purchased from Sigma Aldrich Chemical (St. Louis, MO) and dissolved 
in 0.9% saline. The dose of pilocarpine (4.0 mg/kg) was based on previous experiments showing 
significant induction of jaw movements at this dose (see Collins et al. 2010a for further details). 
2.3. Surgical Procedures  
Rats were anesthetized with a 1.0 ml/kg IP injection of a cocktail solution containing 10.0 
ml of 100mg/mL ketamine plus 0.75 ml of 20.0mg/ml xylazine (Phoenix Scientific, Inc., St. 
Joseph, MO, USA). Rats were placed in a stereotaxic frame (Kopf, Tujunga, CA, USA), and a 
midline scalp incision was made. Two electrode arrays consisting of 50µm tungsten wire 
(California Fine Wire Company, Grover Beach, CA) were bilaterally implanted with a 27-gauge 
needle approximately 5.0 mm deep into the lateral temporalis muscle (4 EMG electrodes per 
animal). Previous research has demonstrated that the lateral temporalis muscle is the jaw muscle 
that shows activity most closely related to TJMs (Cousins et al., 1998). Burr holes were drilled 
through the skull over the STN (R hemisphere) and M1 (L hemisphere), and two –four electrode 
arrays were implanted (8 LFP electrodes per animal). LFP electrode arrays were comprised of 
four linearly spaced 50µm tungsten wires (California Fine Wire Company, Grover Beach, CA). 
Electrode wire was arranged and separated by fused silica tubing (Polymicro Tubing, Phoenix, 
AZ), attached to female pins (Omnetics, Minneapolis, MN) and secured in a rectangular five by 
four pin array.  Two stainless steel watch screws driven into the skull above the cerebellum 
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served as indifferent and ground electrodes. Supplementary anchor screws were positioned as 
necessary and the entire head-stage ensemble was fortified with dental acrylic. The surgical 
coordinates, for which bregma and the top of the skull was used as the reference point, were as 
follows: STN (AP: -3.6, ML: +/- 2.5, DV: -7.5); M1 (AP +1.0, ML +1.9, DV -2.5). Rats 
recovered for one-week post-surgical procedure. 
2.4. Behavioral Measures  
 
Following a one-week recovery period, rats were given an acute IP injection of saline 
(vehicle). Immediately after vehicle injection, rats were placed into a Plexiglas observation 
chamber and allowed to habituate for 10 min. At the beginning of this habituation period, the 
animals were connected to the recording apparatus by a multi-channel tether (Neuralynx, 
Bozeman, MT) that was attached to a pulley system in the ceiling. Following the habituation 
period, a trained observer counted tremulous jaw movements for fifteen minutes. TJMs were 
defined as rapid vertical deflections of the lower jaw that resembled chewing but were not 
directed at any particular stimulus (Salamone et al. 1998). At the end of the 15-minute 
observation period, rats were disconnected and returned to their home cages. This procedure was 
repeated with administration of 4.0mg/kg pilocarpine 24 hours later.  
2.5. Electrophysiological Data Acquisition and Analysis 
Following the habituation period, wide-band electrical activity was recorded (5050.5 
samples/sec) for 15 minutes using a Neuralynx data acquisition system (Bozeman, MT). TJMs 
were counted simultaneously by a trained observer and noted using event markers through 
Cheetah data acquisition software (version 5.6.3; Neuralynx, Bozeman, MT).  Following data 
acquisition and during subsequent offline analysis, data were imported into Matlab R2014a 
(Mathworks, Natick, MA). The raw EMG signal was bandpass filtered between 500 and 1500 Hz 
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and the Hilbert transform was computed on the bandpass filtered signal.  In this regard, the 
instantaneous (5050.5 samples/sec) EMG envelope amplitude (magnitude of Hilbert transform) 
was obtained over time. The EMG signal was then full wave rectified and all raw EMG traces 
presented in the current analysis represent this full wave rectified signal.  Event markers were 
simultaneously imported into Matlab and plotted along with the EMG signal.  The presence or 
absence of these event markers was used to identify TJM and no TJM epochs, respectively. Raw 
LFP data were imported into Matlab R2014a and down-sampled by a factor of 10 during offline 
analysis, thus changing the sampling rate to 505.05 samples/s (Hz; 5050.5/10 = 505.05).  The 
raw LFP signal was lowpass filtered to remove high frequency chewing, chattering and/or teeth 
grinding artifacts (Fc = 200 Hz).  Then, the LFP signal was bandpass filtered for tremor (3-7 Hz) 
and beta frequency (15-30 Hz) and the Hilbert transform was computed on the bandpass filtered 
signals.  Data were examined during: 1) TJM epochs and, 2) No TJM epochs. 
All data analysis was conducted using custom written programs in MatLab R2014a 
(Mathworks, Natick, MA).  Power spectral density estimates were obtained using Welch’s 
averaged modified periodogram method (Welch, 1967) during epochs of TJMs and no TJMs. To 
extract the amplitude modulation (AM) frequency of the EMG signal (e.g., “tremor frequency”; 
3-7 Hz), power spectral density estimates were obtained from the envelope (magnitude of Hilbert 
transform) of the bandpass filtered EMG signal.  For LFP data, the power for tremor (3-7 Hz) 
and beta frequency (15-30 Hz) was calculated from the bandpass filtered signals and represented 
in units of mV2. Average power was calculated by taking the sum of the power values within a 
given frequency range of interest (e.g., 3-7 Hz) and multiplying the sum by the spectral window 
resolution. Centroid frequency or the weighted mean was calculated by first isolating the 
frequency range of interest (e.g., 3-7 Hz), indexing the power values within that frequency range 
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and multiplying them. Then, we divided those values by the sum of the previously indexed 
power values.  Lastly, we took the sum of the aforementioned. 
 
 
2.6. Statistics 
For each of the 5 animals a representative 2.2 second TJM was identified by a trained 
observer using event markers.  The TJM length was determined by the lowest responding animal.  
Further, within the same recording for each animal a subsequent 2.2 second no TJM time point 
was isolated as indicated by lack of event markers.  For each electrode, the average power and 
centroid frequency was computed within the frequency range of interest (3-7 Hz and 15-30 Hz) 
for TJM and no TJM epochs all the while discretized by electrode location (M1 and STN).  
Paired samples t-tests were computed to asses if there were significant differences in 1) average 
tremor power during TJMs and no TJMs for M1, 2) average tremor power during TJMs and no 
TJMs for STN, 3) average beta power during TJMs and no TJMs for M1, 4) average beta power 
during TJMs and no TJMs for STN, and 5) the same as 1-4, but for centroid frequency.  Further, 
we computed paired-samples t-tests to examine if there were differences in the aforementioned 
indices as a function of brain area (M1 and STN).  Lastly, paired samples t-tests were used to 
confirm significant differences in number of TJMs per fifteen-minute recording period across 
vehicle and pilocarpine recordings.  
2.7. Histology 
At the completion of the experiment, animals were deeply anesthetized with CO2 and 
perfused with 0.9% physiological saline followed by 3.7% formaldehyde solution.   The brains 
were extracted and stored in the formaldehyde solution for one week.   Then, brains were sliced 
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(50 µm sections) using a vibratome (Leica, Germany), mounted, Nissl stained using Cresyl 
Violet and cover-slipped allowing for verification of electrode placements.  Photomicrographs of 
electrode tracks were taken using a Nikon microscope connected to a Spot RT camera system, 
digitized and prepared for presentation using Adobe Photoshop.  Consistent with the histological 
criteria employed by Brown et al. (2011) only placements that were within 500 µm of the STN, 
but dorsal to the cerebral peduncles and internal capsule were used for statistical analyses.    
 
3. Results 
3.1. Histological verification of electrode placements 
A total of 37 LFP electrodes (n= 19 M1 electrodes; n=19 STN electrodes) and 5 EMG 
electrodes across 5 animals were used in the current analysis. All animals contributed 1 EMG 
electrode, 3-4 M1 (Figure 1A) and 3-4 STN (Figure 1B) electrodes.  All EMG and LFP data 
were simultaneously recorded from each animal.  M1 electrodes terminated in all cortical layers 
but were more likely to terminate in deeper layers. Further, most STN electrodes were hits, 
although a few terminated slightly dorsally or anteriorly (data not shown), but still within the 500 
µm criteria put forth by Brown et al. (2011). 
 Figure 1: Verification of electrode placements.
representative and simultaneously recorded sites in M1.  Middle and right photomicrographs 
show 4x and 10x close-up of electrode tips, respectively. 
different animal.  B (top): Photomicrograph
and right photomicrographs show a 4x and 10x close
(bottom): Same as B (top) but for a different animal.  
 
3.2. Pilocarpine induces TJMs in the tremor frequency range (3
 Administration of pilocarpine significantly induced TJMs compared to vehicle control 
(Pilo mean: 603.6 + 314.4; Veh mean: 14.4 
 
 A (top): Photomicrographs of four 
A (bottom):  Same as A (top) but for a 
s of a representative recording site in STN.  Middle 
-up of electrode tips, respectively.  
 
-7 Hz) as reflected by EMG
+ 9.8; t(4) = 4.3, p <. 05).  Although vehicle 
14
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conditions were used to verify the ability of pilocarpine to produce TJMs, large behavioral 
differences existed between vehicle and pilocarpine recordings that made electrophysiological 
comparisons between these two signals unsuitable (i.e., no tremor bursts, but more movement 
artifact, under vehicle conditions). Because of these differences, all EMG and LFP data analysis 
were conducted on epochs of TJMs and no TJMs within the pilocarpine recording for each 
animal.    
  During bouts of jaw movement activity, the bandpass filtered (500-1500 Hz) and full 
wave rectified EMG signal was marked by rhythmic activity in the 3-7 Hz range (Figure 2A top, 
left; red).  Conversely, during periods of quiescence, no rhythmic activity was observed in the 
EMG (Figure 2A bottom, left; blue).  Spectrograms indicated the same pattern of activity as the 
filtered EMG traces (Figure 2A, right). For the traces presented in Figure 2A, power spectral 
analysis revealed strong rhythmicity in the envelope of the EMG signal with a fundamental 
frequency of 4 Hz along with robust 2nd and 3rd harmonics (Figure 2B, red). Epochs of 
quiescence failed to exhibit amplitude modulation of the EMG signal within the tremor 
frequency range (Figure 2B, blue) and, show relatively little power overall.  Upon examination 
of the entire pilocarpine recording for the same representative animal, rodents continued to 
exhibit dominant power of the EMG envelope within the tremor frequency range, although the 
harmonics were largely attenuated (Figure 2C).  Importantly, this animal exhibited TJMs for 
23.15% (3.47/15 minutes) of the recording session (Figure 2C right) indicating the robustness 
of the observed phenomenon. 
 Figure 2: Pilocarpine induces TJMs in the tremor f
activity. A (top): EMG electrode trace bandpass filtered for EMG frequency (500
full wave rectified during a long epoch of TJMs (red; 7.3 seconds) for a representative animal.  
The spectrogram indicates the same pattern of rhyth
Same animal and recording as presented in A, but for a long period of quiescence (blue; 7.3 
seconds).  The spectrogram indicates little rhythmic activ
Power spectrum of the EMG envelope for the same traces as presented in A.  As can be seen, 
there is clear 3-7 Hz rhythmicity and strong harmonics during TJM epochs, which is absent 
during periods of quiescence.  C (left)
TJM and no TJM epoch isolation) for the same animal as presented in A and B.  
Behavior of the same animal as presented prev
 
3.3. Power in the tremor frequency band increases 
 Upon examination of simultaneously recorded M1 LFPs for the same animal as in 
2, the raw (Figure 3A top) and bandpass filtered (3
revealed increased power in the tremor frequency band du
red), but not during bouts of quiescence (
requency range as reflected by EMG 
mic activity as the EMG trace. 
ity during bouts lacking TJMs. 
: Power spectrum of the entire pilocarpine re
iously across the entirety of pilocarpine recording.  
during TJMs in M1 and STN 
-7 Hz; Figure 3A middle
ring epochs of TJMs (
Figure 3A right, blue). The LFP signal was indexed 
16
-1500 Hz) and 
A (bottom): 
B: 
cording (sans 
C (right): 
 
Figure 
) LFP signals 
Figure 3A left, 
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during epochs of TJMs and no TJMs as indicated by EMG event markers or lack thereof, 
respectively. Spectrograms of the raw signal revealed differential patterns of LFP activity for 
bouts of TJMs and quiescence (Figure 3A bottom).  The power spectrum of the raw LFP signal 
filtered for tremor frequencies (3-7 Hz) during epochs of TJMs (red) and no TJMs (blue) 
indicated strong LFP power in the tremor range with a peak at ~4 Hz for bouts of TJMs, while 
little LFP power existed at such frequencies for bouts lacking TJMs. At a simultaneously 
recorded STN site, the same pattern of activity was present (Figure 3B).  Overall, the bandpass 
filtered LFP signal (3-7 Hz) during bouts of TJMs and the subsequent power spectrum of that 
signal revealed strong power in the 3-7 Hz range, whereas bouts of quiescence did not exhibit 
this effect (Figure 3B).  
Summary data from all animals revealed the same pattern of effects. Overall, M1 LFPs 
during TJM epochs (red) exhibited significantly more power in the 3-7 Hz range as compared to 
no TJM (blue) epochs (Figure 3C; t(18) = 5.13, p < .05).  The same pattern of activity existed 
for STN recording sites (Figure 3C, right; t(18) = 4.55, p < .05).  Further, M1 exhibited more 
power in the tremor band during TJM and no TJM epochs compared to STN (TJM: t(18) = 3.47, 
p < .05; no TJM: t(18) = 3.26, p < .05). Analysis of centroid frequency (Figure 3D) revealed no 
differences between bouts of TJMs and no TJMs within a given brain area (e.g., M1 TJM vs. M1 
no TJM; M1: t(18) = -0.79, p > .05; STN: t(18) = -0.36, p > .05 ).  Moreover, there were no 
significant differences in LFP centroid frequency between TJM and no TJM epochs across brain 
areas (e.g., M1 TJM vs. STN TJM; TJM: t(18) = 0.51, p > .05; No TJM: t(18) = 1.88, p > .05). 
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Figure 3: Power in tremor frequency band increases during TJMs in M1 and STN. A: Raw 
(top) and bandpass filtered (3-7 Hz; middle) M1 LFP traces during epochs of TJMs (red) and no 
TJMs (blue) for the same representative animal presented in Figure 2. A (bottom): 
Corresponding spectrograms for the raw M1 signal presented in the top panel of A during TJM 
and no TJM epochs.  Overall, the spectrograms indicate rhythmicity in the LFP during periods of 
TJMs that is lacking during periods of quiescence. A (right): Power spectrum of the bandpass 
filtered LFP signal presented in the middle panel of A during the TJM and no TJM epoch.  
Tremor frequency power increases substantially during periods of TJMs, while little tremor 
power exists during epochs of quiescence.  B: Same as A, but for a simultaneously recorded STN 
site for the same representative animal presented in panel A. C: Summary data for tremor 
frequency power across all animals for TJM and no TJM epochs for M1 and STN.  As can be 
seen, tremor band power dominates during the presence of TJMs, but not for bouts lacking 
TJMs.  D:  Summary data across all animals for tremor band centroid frequency as a function of 
TJM and no TJM epochs for M1 and STN recording sites.  Overall, there were no differences in 
centroid frequency across behavioral state or brain area.   
 
3.4. Beta band power does not increase during TJMs in M1 and STN 
 Simultaneously recorded M1 LFPs for the animal shown in Figure 2 and 3, revealed 
similar LFP beta band power during epochs of TJMs (Figure 4A left, red) and epochs of 
quiescence (Figure 4A right, blue) for the raw (Figure 4A top) and bandpass filtered (15-30 
Hz; Figure 4A middle) LFP signals. Importantly, the data shown here are for the same time 
points as presented in Figure 2 and 3, but here data were filtered for beta (15-30 Hz) instead of 
tremor frequencies (3-7 Hz). A closer look at the signal revealed similar instantaneous 
fluctuations in the LFP during active (Figure 4A bottom, left) and quiet (Figure 4A bottom, 
right) bouts. The power spectrum of the raw LFP signal filtered for beta band activity during 
epochs of TJMs (red) and no TJMs (blue) revealed strong LFP beta band power, but no 
alterations in power across behavioral state (e.g., bouts of TJMs vs. no TJMs). At a 
simultaneously recorded STN site, the same pattern of activity was present (Figure 4B).   
Overall, the bandpass filtered LFP signal (15-30 Hz) and subsequent power spectrum of that 
 signal during epochs of TJMs and quiescence revealed no differences in beta band power 
(Figure 4B).  
Summary data from all animals demonstrate the same trend as represented in 
4A/B. Overall, M1 LFPs during TJM epochs (red) and no TJM epochs (blue) exhibited similar 
levels of beta band power (Figure 4C
activity existed (Figure 4C, right
power during epochs of TJMs and no TJMs as compared to STN (TJM: t(18) = 2.76, 
TJM: t(18) = 3.12, p < .05).  Moreover, TJM epochs exhibited lower centroid beta band 
frequency compared to no TJM epochs for both M1 and STN (
.05; STN: t(18) = -3.57, p < .05, respectively).  Further, beta band frequency was higher in M1 
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 Figure 4: Beta band power does not increase during TJMs in M1 and STN. A
bandpass filtered (15-30 Hz; middle) M1 LFP traces during epochs of TJMs (red) and no TJMs 
(blue) for the same representative animal presented in Figure 2 and 3. 
seconds of the middle panel of A to show instantaneous LFP fluctuations. 
spectrum of the bandpass filtered LFP signal presented in the middle panel of A during the TJM 
and no TJM epoch.  Beta frequency power does not increase during periods of TJMs, while little 
B: Same as A, but for a simultaneously recorded STN 
presented in panel A. C: Summary data for beta band power across all animals for TJM and no 
TJM epochs for M1 and STN.  As can be seen, beta band power is similar during across 
behavioral states.  D:  Summary data ac
function of TJM and no TJM epochs for M1 and STN recording sites. 
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2010; Podurgiel et al., 2013a), conditional neural knockout of adenosine A2A receptors 
(Salamone et al., 2013), and deep brain stimulation of the STN (Collins-Praino et al., 2012). 
Evidence indicates that the TJMs induced by pilocarpine are due to stimulation of M2 or M4 
muscarinic receptors in the ventrolateral neostriatum of the rat, which is the homologue of the 
ventral putamen of primates (Salamone et al., 1990, 1998; Mayorga et al., 1997, 1999). For these 
reasons, pilocarpine was selected for the present studies in order to induce a robust oral tremor 
that would allow for the assessment of tremor-related cortical and subthalamic LFP activity. 
 Network activation as measured by LFP activity in M1 and STN can be used as a tool to 
better understand transient dynamics across distributed neural networks. Similar to analysis of 
variations in the blood-oxygen-dependent signal used in functional neuroimaging (Logothetis 
and Wandell, 2004; Law et al., 2005), detailed analysis of mesoscopic signals such as the LFP 
and EEG reveal the engagement of distributed neural circuits in relation to tremorogenesis— a 
cardinal symptom of Parkinsonism.  Abnormalities in long-range connectivity between brain 
areas have been postulated as an important pathophysiological mechanism underlying brain 
dysfunctions (Hutchison et al., 2004; Mallet et al., 2008).  However, it remains unclear how 
perturbed connectivity relates to motor symptoms such as tremorogenesis, and how it is 
manifested in the dynamic interactions of neuronal circuits. 
In the present study, we simultaneously recorded LFPs from the primary motor cortex 
and subthalamic nucleus as well as EMG from the lateral temporalis muscle in a rat model of 
drug-induced tremor. The temporalis was chosen because of previous research indicating that 
activity of this jaw closing muscle is a critical marker of observable TJM activity (Cousins et al., 
1998). The present results indicate that administration of the muscarinic agonist pilocarpine 
induces TJMs in rats that fall into the frequency range associated with Parkinsonian resting 
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tremor (3-7 Hz), with a peak frequency of approximately 4 Hz, and harmonics at higher 
frequencies. These data are consistent with previous studies indicating that cholinomimetic 
drugs, including muscarinic agonists and anticholinesterases, can induce or exacerbate resting 
tremor. Administration of the anticholinesterase physostigmine to PD patients was reported to 
exacerbate parkinsonian symptoms, including tremor, and these motor deficits were attenuated 
by coadministration of centrally-acting muscarinic antagonists (Duvoisin 1967). For many 
decades, non-selective muscarinic receptor antagonists have been used to treat idiopathic and 
drug-induced Parkinsonism (McEvoy, 1983). Anticholinesterases are prescribed to treat the 
cognitive deficits associated with Alzheimer’s Disease (see Birks, 2006 for review), and these 
drugs have been shown to induce Parkinsonian symptoms, including tremor, as side effects (Ott 
and Lannon, 1992; Arai, 2000; Aarsland et al., 2003; Grace et al., 2009). In animal studies, 
muscarinic agonists such as tremorine and oxotremorine have been widely recognized to act as 
tremorogenic agents (Brimblecombe, 1975). Furthermore, muscarinic agonists and 
anticholinesterases induce TJMs in rodents, and co-administration of antiparkinsonian agents 
including DA agonists, muscarinic antagonists, and adenosine A2A antagonists have been shown 
to reduce cholinomimetic-induced TJMs (Salamone et al. 1986; Baskin et al., 1994; Mayorga et 
al., 1997; Salamone et al., 1998; Simola et al., 2004, 2006; Miwa et al., 2009; Collins et al., 
2010a, 2011).  
 The induction of TJMs by pilocarpine was associated with strong rhythmicity in the 
envelope of the EMG signal with a peak frequency of approximately 4 Hz along with robust 
second and third harmonics, which is consistent with EMG recordings from the forearms of PD 
patients during periods of tremor (Liu et al., 2002; Timmerman et al., 2003; Wang et al., 2005; 
Reck et al., 2009; Hirschmann et al., 2013). This EMG activity was accompanied by an increase 
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in power at tremor frequency (3-7 Hz) in M1 and the STN. In PD patients, pathological 
oscillatory neuronal activity in the open and closed loop connections between the cortex, basal 
ganglia, and thalamus is thought to underlie tremorogenesis (Hutchison et al., 2004). 
Simultaneously recorded magnetoencephalography and forearm EMG in PD patients has allowed 
researchers to characterize the cortical regions that are coherent with muscle activity during 
periods of resting tremor (Oswal et al., 2013). These studies indicate a strong coherence between 
EMG of forearm muscles and M1 activity at tremor frequency and its second harmonic 
(Timmerman et al., 2003).  
 Oscillatory activity in the STN of PD patients has been well characterized, as researchers 
are able to record LFPs from patients undergoing implantation of stimulating electrodes for deep 
brain stimulation. In recent years, the primary focus has been on increased oscillatory activity in 
the beta band (~15-30 Hz), since there is evidence that increased beta power in the STN is 
associated with motor control, particularly akinesia-rigidity (Brown et al., 2001; Levy et al., 
2002; Priori et al., 2004; Brown and Williams, 2005; Kuhn et al., 2006). Conversely, resting 
tremor has not been shown to correlate with beta band activity in the STN of PD patients (Kuhn 
et al., 2005). Instead, the development of tremor has been associated with the emergence of 
oscillations in the tremor frequency range (3-7 Hz) as indicated by power spectra of STN LFPs, 
and coherence between STN LFPs and EMG activity at tremor frequency (Brown et al., 2001; 
Levy et al., 2000; Liu et al., 2002; Wang et al., 2005; Reck et al., 2009; Hirschmann et al., 2013). 
In a recent study by Hirschmann et al. (2013) the emergence of tremor in PD patients was shown 
to be associated with an increase of cerebral synchronization at tremor frequency and second 
harmonic in a network that includes both STN and M1. Additionally, in African green monkeys 
treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the development of resting 
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tremor was associated with the emergence of oscillations at tremor frequency in the STN 
(Bergman et al., 1994). Results from our experiment are line with the findings reported in the 
clinical and non-human primate studies, as we saw increased power in M1 and STN in the 
tremor, but not beta frequency range during periods of TJMs. Moreover, the present results are 
consistent with previous studies demonstrating that the STN is a critical part of the basal ganglia 
circuitry that is involved in motor dysfunctions related to Parkinsonism. Lesions or inactivation 
of STN have been shown to reverse motor dysfunctions in rodent models (Centonze et al., 2005; 
Baunez and Gubellini 2010). In addition, high frequency stimulation of STN has been reported to 
restore motor function in rodent models of Parkinsonism (Baunez 2011; Brown et al., 2011), and 
to attenuate drug-induced TJMs in rats (Collins-Praino et al., 2011).   
To date, this phenomenon has been well documented in the clinical literature, but very 
little has been done to study these oscillatory alterations in rodent models. It has, however, been 
shown that LFPs recorded from the frontal cortex and STN of rats with 6-hydroxydopamine 
lesions of midbrain dopaminergic neurons show increased power and coherence in the beta 
frequency band (Sharott et al., 2005; Mallet et al., 2008). It should be noted that these studies 
were using a model that involved neurotoxic depletion of DA, whereas our study employed a 
model of drug-induced Parkinsonian resting tremor. In the present study, though the rats 
appeared to have reduced locomotion after pilocarpine administration, they were not completely 
akinetic, and occasionally moved about the chamber during recording. Therefore, our study 
specifically evaluated the physiological correlates of tremor by using an agent that induces a 
robust tremorogenic (i.e., TJM) response. By providing physiological and behavioral correlates 
of tremor, this model could be utilized in preclinical studies focused on the development of 
Parkinsonian treatments that specifically target tremor. 
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